Article · 24 Jan 2024
Review articlePublished 2016
Immunomodulation of Glatiramer Acetate in Multiple Sclerosis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease in central nervous system (CNS) characterized by demyelination as well as axonal and neuronal degeneration. Glatiramer acetate, is a mixture of synthetic polypeptides comprising four amino acids resembling the myelin basic protein (MBP), and approved as an immunoregulatory drug for the treatment of relapsing-remitting MS. The mechanism of action of GA in MS patients and the animal model experimental autoimmune encephalomyelitis (EAE) were extensively investigated over years. The cumulative findings indicate GA exerts its therapeutic activity by immunomodulating various levels of the immune response. This includes the blockade of major histocompatibility complex (MHC) molecules, T cell receptor antagonist, induction of GA-specific suppressor Th2 cells, an increase in frequency and function of CD4+CD25+FoxP3+ regulatory T cells, the down-regulation of Th1 and Th17 differentiation; the development of type II antigen presenting cells (APCs). In the review, we aim to provide a comprehensive overview of the immunoregulatory properties of GA in adaptive and innate immune response, in particular on the CD4+ effector T cells.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Neuroscience and Neuropharmacology.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neuroscience and Neuropharmacology
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Chunhua Chen”
